ARRY-371797 is a clinical stage, oral, p38α (MAPK14
)-selective kinase inhibitor that was originally developed by Array BioPharma (a Pfizer owned company since mid-2019) for anti-inflammatory and analgesic potential [2
]. However, development for chronic inflammatory diseases has since been terminated. No results from completed analgesia trials have been published. Subsequent repositioning has seen the focus transfer to ARRY-371797 for LMNA-related dilated cardiomyopathy. p38α signalling is hyperactivated in mice with cardiomyopathy caused by lamin A/C gene (LMNA
) mutation [3
] and p38α activation is observed in the hearts from human subjects with LMNA-related dilated cardiomyopathy, thus ARRY-371797 has been advanced as a therapeutic option for this indication.